Novartis' drug delivery deal with Alteogen; More worker cuts at Cellares

PartnershipALT-B4Positive

AI Analysis

Summary

Novartis entered a licensing deal with Alteogen for the hyaluronidase enzyme ALT-B4, manufactured using Alteogen's tech platform. The article also mentions workforce cuts at Cellares and news regarding other biotech companies.

Outcome Details

Novartis licensing Alteogen's hyaluronidase enzyme ALT-B4

Importance:6/10

Sentiment:

0.30

licensing dealdrug deliveryenzyme technologypartnershipworkforce reduction

Related Companies

$NVS

Read the original article

Published by Endpoints News on September 3, 2026 3:30 PM

Read Original